Serum miR-122 levels correlate with diabetic retinopathy

Pastukh, Nina; Meerson, Ari; Kalish, Dorina; Jabaly, Hanin; Blum, Arnon

doi:10.1007/s10238-019-00546-x

Cited by 37 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, several works have investigated the association of miRNAs with DR (23)(24)(25)(26)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52). In circulating miRNA profiling studies, miR-27b, miR-320a, and miR-126 were validated in patients with type 1 diabetes and DR (23,42).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

et al. 2020

View full text Add to dashboard Cite

Objective: Recently, the role of circulating miRNAs as non-invasive biomarkers for the identification and monitoring of diabetes microvascular complications has emerged. Herein, we aimed to: identify circulating miRNAs differentially expressed in patients with and without diabetic retinopathy (DR); examine their predictive value; and understand their pathogenic impact. Methods: Pooled serum samples from randomly selected matched patients with type 2 diabetes, either with or without DR, were used for initial serum miRNA profiling. Validation of the most relevant miRNAs was thereafter conducted by RT-qPCR in an extended sample of patients with DR and matched controls. Results: Following miRNA profiling, 43 miRNAs were significantly up-or down-regulated in patients with DR compared with controls. After individual validation, 5 miRNAs were found significantly overexpressed in patients with DR. One of them, miR-1281, was the most up-regulated and appeared to be specifically related to DR. Furthermore, secreted levels of miR-1281 were increased in high glucose-cultured retinal cells, and there was evidence of a potential link between glucose-induced miR-1281 up-regulation and DR. Conclusion: Our findings suggest miR-1281 as a circulating biomarker of DR. Also, they highlight the pathogenic significance of miR-1281, providing insights for a new potential target in treating DR.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…DME associated with PDR would probably have provided new information in any way, but interpretation of the results would have been more difficult due to the ischemic component that characterizes PDR. In fact, based on results in human serum [ 11 , 23 ] and in animal models of diabetic retinopathy [ 2 , 3 , 4 , 5 , 6 , 7 ], different stages of DR seem to be associated with different expression of both miRNAs and cytokines. Moreover, we enrolled only T2D patients on the basis of the different etiopathological mechanisms that distinguish T2D from T1D [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema

Grieco

Sebastiani

Eandi

et al. 2020

IJMS

View full text Add to dashboard Cite

We identified and compared secreted microRNA (miRNA) expression in aqueous humor (AH) and plasma samples among patients with: type 2 diabetes mellitus (T2D) complicated by non-proliferative diabetic retinopathy (DR) associated with diabetic macular edema (DME) (DME group: 12 patients); T2D patients without DR (D group: 8 patients); and non-diabetic patients (CTR group: 10 patients). Individual patient AH samples from five subjects in each group were profiled on TaqMan Low Density MicroRNA Array Cards. Differentially expressed miRNAs identified from profiling were then validated in single assay for all subjects. The miRNAs validated in AH were then evaluated in single assay in plasma. Gene Ontology (GO) analysis was conducted. From AH profiling, 119 mature miRNAs were detected: 86 in the DME group, 113 in the D group and 107 in the CTR group. miRNA underexpression in the DME group was confirmed in single assay for let-7c-5p, miR-200b-3p, miR-199a-3p and miR-365-3p. Of these four, miR-199a-3p and miR-365-3p were downregulated also in the plasma of the DME group. GO highlighted 54 validated target genes of miR-199a-3p, miR-200b-3p and miR-365-3p potentially implied in DME pathogenesis. Although more studies are needed, miR-200b-3p, let-7c-5p, miR-365-3p and miR-199a-3p represent interesting molecules in the study of DME pathogenesis.

show abstract

“…Notably, in the same individuals, only a few circulating miRNAs were detected in vitreous compared with serum [10]. In ▶ table 1, we have summarized miR-126 [11,12], miR-211 [13], miR-93 [14][15][16], miR-122 [17], miR-221 [18], miR-27b and miR-320a [8], miR-150-5p, miR-21-3p and miR-30b-5p [19] as biomarkers in DR over the past 5 years. At the same time, we have focused on miRNAs in vitreous humor (VH) of DR, such as miR-126 [20], miR-19a and 27a [21], miR-29a [22,23], miR-93 and 20a [21], and miR-200b [24] in ▶ table 2.…”

Section: Circulating Mirnas As Biomakers In Drmentioning

confidence: 99%

MicroRNAs: Potential Targets in Diabetic Retinopathy

Wang

et al. 2020

Horm Metab Res

View full text Add to dashboard Cite

Diabetic retinopathy (DR), a serious microvascular complication of diabetes, is a leading cause of blindness in adults. The pathogenesis of DR involves a variety of tissues and complex mechanisms, such as inflammation, oxidative stress, optic neurodegeneration, and autophagy. Nowadays, microRNAs (miRNAs), a novel group of non-coding small RNAs, have been extensively studied and recognized to play a key role in the pathogenesis of DR through aforementioned pathways. Furthermore, some miRNAs have been proposed as biomarkers that may be utilized to screen for DR. Also, miRNAs are a new therapy for DR. In this review, we summarize several miRNAs and, their roles in the pathogenesis of DR. miRNAs, as potential pharmacological targets for the diabetic retinopathy, may provide new insights for the treatment of DR.

show abstract

Serum miR-122 levels correlate with diabetic retinopathy

Cited by 37 publications

References 34 publications

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy

MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema

MicroRNAs: Potential Targets in Diabetic Retinopathy

Contact Info

Product

Resources

About